West Pharmaceutical Services/$WST
1D1W1MYTD1Y5YMAX
Capital at risk
About West Pharmaceutical Services
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
- Ticker
- $WST
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 10,800
- Headquarters
- Exton, United States
- Website
- www.westpharma.com
WST Metrics
BasicAdvanced
$24B
43.53
$7.81
1.16
$0.88
0.26%
Price and volume
Market cap
$24B
Beta
1.16
52-week high
$386.00
52-week low
$223.83
Average daily volume
548K
Dividend rate
$0.88
Financial strength
Current ratio
2.822
Quick ratio
1.792
Long term debt to equity
9.839
Total debt to equity
10.585
Dividend payout ratio (TTM)
11.05%
Interest coverage (TTM)
147.88%
Profitability
EBITDA (TTM)
912.2
Gross margin (TTM)
36.79%
Net profit margin (TTM)
16.98%
Operating margin (TTM)
22.23%
Effective tax rate (TTM)
20.34%
Revenue per employee (TTM)
$310,000
Management effectiveness
Return on assets (TTM)
11.51%
Return on equity (TTM)
19.09%
Valuation
Price to earnings (TTM)
43.534
Price to revenue (TTM)
7.342
Price to book
8
Price to tangible book (TTM)
8.32
Price to free cash flow (TTM)
55.909
Free cash flow yield (TTM)
1.79%
Free cash flow per share (TTM)
6.081
Dividend yield (TTM)
0.26%
Forward dividend yield
0.26%
Growth
Revenue change (TTM)
12.38%
Earnings per share change (TTM)
16.82%
3-year revenue growth (CAGR)
5.10%
10-year revenue growth (CAGR)
8.63%
3-year earnings per share growth (CAGR)
4.38%
10-year earnings per share growth (CAGR)
18.99%
3-year dividend per share growth (CAGR)
5.07%
10-year dividend per share growth (CAGR)
6.35%
What the Analysts think about WST
Analyst ratings (Buy, Hold, Sell) for West Pharmaceutical Services stock.
Analyst projections of the future price of West Pharmaceutical Services stock.
Bulls say / Bears say
Q4 2025 net sales of $805.0 million grew 7.5% year-over-year (3.3% organic), driven by a 20.3% increase in HVP Components (15.1% organic), highlighting robust demand for high-value injectable product offerings. (West Q4 2025 Results (investor.westpharma.com))
In Q1 2026 West topped sales and profit estimates and on April 23 raised its full-year 2026 net sales guidance to $3.295 billion–$3.350 billion and adjusted EPS forecast, reflecting sustained strong demand across its portfolio. (Reuters (sahmcapital.com))
West authorized a $1 billion share repurchase program in February 2026, demonstrating management’s commitment to returning capital and supporting per-share metrics. (Reuters (sahmcapital.com))
HVP Delivery Devices net sales fell 16.9% year-over-year (18.1% organic decline) in Q4 2025, underscoring volatility in this high-value product line. (West Q4 2025 Results (investor.westpharma.com))
CEO Eric M. Green’s planned retirement in H2 2026 introduces potential leadership and strategic continuity risks during the succession process. (West 8-K Mar 9 2026 (sec.gov))
The mid-year divestiture of the SmartDose® 3.5 mL system removes approximately $55 million of second-half 2025 revenues, creating a headwind to reported organic growth in fiscal 2026. (West Q4 2025 Guidance (investor.westpharma.com))
Data summarised monthly by Lightyear AI. Last updated on 12 Aug 2026.
WST Financial Performance
Revenues and expenses
WST Earnings Performance
Company profitability
Upcoming events
No upcoming events
WST News
AllArticlesVideos
Funds containing WST
AllEURGBPUSD
Fund name | Fund size | $WST weighting |
|---|---|---|
iShares S&P 500 Health Care Sector€IUHE | €125M | 0.39% |
iShares MSCI World Health Care Sector Advanced€CBUF | €606M | 0.23% |
iShares S&P 500 Equal Weight€O4J0 | €4.4B | 0.19% |
iShares S&P 500 Equal Weight£EWSP | £3.7B | 0.19% |
iShares MSCI USA SRI$SUAS | $3.4B | 0.17% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.